Arca
Skip to content
Tools
Tools

Somatostatin receptor

Family in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 2
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 5

Who is on it, and how far along

Every drug ChEMBL records acting on SSTR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 3

Approved2

  • Lutetium oxodotreotide
  • Octreotide

Phase 31

  • Somatostatin

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Lutetium oxodotreotideApprovedNovartis PharmaceuticalsProtein or peptideBinding agentSomatostatin receptor binding agent50
      OctreotideApprovedNovartis PharmaceuticalsProtein or peptideAgonistSomatostatin receptor agonist50
      SomatostatinPhase 3Nanjing Chia-tai Tianqing PharmaceuticalProtein or peptideAgonistSomatostatin receptor agonist87

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov.
      Application of 18F-SSTR2 Antagonist PET/CT in Neuroendocrine TumorsOctreotideNot applicableRecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNov 19, 2026
      Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesOctreotide, Somatostatin—Enrolling by invitationChiyi ChenNov 3, 2026
      TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETSLutetium oxodotreotidePhase 3Not yet recruitingTata Memorial HospitalNov 2, 2026
      A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy VolunteersSomatostatinPhase 1RecruitingNanjing Chia-tai Tianqing PharmaceuticalNov 2, 2026
      Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsOctreotide, SomatostatinPhase 3RecruitingWashington University School of MedicineSep 25, 2026
      Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye DiseaseSomatostatin—RecruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversitySep 23, 2026
      Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCTSomatostatinPhase 4RecruitingJianyin ZhouJul 22, 2026
      A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsLutetium oxodotreotide—RecruitingNovartis PharmaceuticalsJun 9, 2026
      A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyOctreotidePhase 3Not yet recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Jun 3, 2026
      Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in SpainSomatostatin—RecruitingGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaJun 3, 2026
      Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior ResectionSomatostatinNot applicableRecruitingTongji HospitalMay 26, 2026
      An Observational Study of Octreotide Subcutaneous Depot in Patients With AcromegalyOctreotide—RecruitingCamurus ABMay 13, 2026
      Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)Somatostatin—Not yet recruitingAzienda USL Reggio Emilia - IRCCSApr 20, 2026
      Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort StudyOctreotide—Active, not recruitingWest China HospitalApr 16, 2026
      Octreotide Microspheres for Preventing Pancreatic FistulaOctreotidePhase 3Not yet recruitingShanghai Zhongshan HospitalMar 18, 2026
      Effect of Insulin Lowering on LipogenesisOctreotidePhase 1RecruitingColumbia UniversityFeb 11, 2026
      PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)Lutetium oxodotreotidePhase 3RecruitingTata Memorial HospitalSep 22, 2025
      Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.Lutetium oxodotreotidePhase 1RecruitingEmory UniversitySep 2, 2025
      A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETsLutetium oxodotreotidePhase 3RecruitingHTA Co., Ltd.Jul 10, 2025
      Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentLutetium oxodotreotidePhase 2RecruitingRTOG Foundation, Inc.May 2, 2025
      Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsLutetium oxodotreotidePhase 3RecruitingGrupo Espanol de Tumores NeuroendocrinosMar 17, 2025
      Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA TrialLutetium oxodotreotidePhase 2 / Phase 3RecruitingThe Netherlands Cancer InstituteMar 3, 2025

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111436, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.